Kristin K. Brown; Michael M. Hann; Ami S. Lakdawala; Rita Santos; Pamela J. Thomas; Kieran Todd
Med. Chem. Commun., 2018, 9, 606-613
https://doi.org/10.1039/C7MD00633K

Abstract

Abstract. The assessment of the suitability of novel targets to intervention by different modalities, e.g. small molecules or antibodies, is increasingly seen as important in helping to select the most progressable targets at the outset of a drug discovery project. This perspective considers differing aspects of tractability and how it can be assessed using in silico and experimental approaches. We also share some of our experiences in using these approaches.